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Background: Obstetric hemorrhage is the leading cause of maternal mortality, particularly in low resource settings
where delays in obtaining definitive care contribute to high rates of death. The non-pneumatic anti-shock garment
(NASG) first-aid device has been demonstrated to be highly cost-effective when applied at the referral hospital (RH)
level. In this analysis we evaluate the incremental cost-effectiveness of early NASG application at the Primary Health
Center (PHC) compared to later application at the RH in Zambia and Zimbabwe.
Methods: We obtained data on health outcomes and costs from a cluster-randomized clinical trial (CRCT) and
participating study hospitals. We translated health outcomes into disability-adjusted life years (DALYs) using
standard methods. Econometric regressions estimated the contribution of earlier PHC NASG application to
DALYs and costs, varying geographic covariates (country, referral hospital) to yield regression models best fit
to the data. We calculated cost-effectiveness as the ratio of added costs to averted DALYs for earlier PHC
NASG application compared to later RH NASG application.
Results: Overall, the cost-effectiveness of early application of the NASG at the primary health care level compared
to waiting until arrival at the referral hospital was $21.78 per DALY averted ($15.51 in added costs divided by 0.712
DALYs averted per woman, both statistically significant). By country, the results were very similar in Zambia, though not
statistically significant in Zimbabwe. Sensitivity analysis suggests that results are robust to a per-protocol outcome
analysis and are sensitive to the cost of blood transfusions.
Conclusions: Early NASG application at the PHC for women in hypovolemic shock has the potential to be
cost-effective across many clinical settings. The NASG is designed to reverse shock and decrease further bleeding
for women with obstetric hemorrhage; therefore, women who have received the NASG earlier may be better able to
survive delays in reaching definitive care at the RH and recover more quickly from shock, all at a cost that is highly
acceptable.
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Ninety-nine percent of the 800 maternal deaths that occur
each day are in developing countries [1]. While global
maternal mortality has been nearly halved from 1990
to 2008, the proportion of maternal deaths in Sub-Saharan
Africa has doubled over the same period [1]. For each
woman who dies, an estimated 20–30 women survive
with morbidities, including infertility, anemia, and de-
pression [2].
Obstetric hemorrhage continues to be the leading cause
of maternal mortality and morbidity worldwideC [3]. Uter-
ine atony, the failure of the uterus to contract after delivery,
accounts for a majority of post-partum hemorrhage (PPH)
cases [3]. Delays in transport, diagnosis and adequate treat-
ment of women experiencing severe hypovolemic shock
due to obstetric hemorrhage are common in settings where
access to resources and care are limited [4].
The non-pneumatic anti-shock garment (NASG) has
been studied as a means to stabilize women with hypovol-
emic shock secondary to obstetric hemorrhage [5-7]. The
NASG is a neoprene compression device that reverses
shock by delivering circumferential counter-pressure to
the lower body, legs, pelvis, and abdomen (see Figure 1)
and decreases blood loss. Use of the garment as a first-aid,
temporizing device can reduce the impact of delays in
reaching definitive care [8].
Several policy initiatives, such as expanding access to
emergency obstetric care, have been established over the
past few decades to improve maternal health, yet the
evidence base on how to implement these policies and
strategies at the health system level remains weak [9].
Scalable health interventions, those that are effective andFigure 1 Image of a non-pneumatic anti-shock garment (NASG) on aefficacious when applied to the larger population, are crit-
ical in reducing maternal mortalities and morbidities [10].
Information on cost-effectiveness is crucial in planning
scale-up and impact of maternal health interventions, but
is often lacking [10-12].
The NASG is considered a cost-effective intervention
for referral hospitals (RH), based on quasi-experimental
studies in Egypt and Nigeria [13]. For women in severe
shock, with a mean arterial blood pressure (MAP) of less
than 60 mmHg, use of the NASG improved health out-
comes by averting 2–3 disability-adjusted life years
(DALYs) per woman and had a net savings or extremely
low cost per DALY averted.
In 2012, the World Health Organization (WHO) rec-
ommended the NASG be used as a temporizing measure
for women with PPH until definitive care, blood transfu-
sions, and/or surgery can be obtained. Our aim was to
evaluate the cost-effectiveness from the payer’s perspec-
tive of early NASG intervention using evidence from a
cluster-randomized controlled trial of early NASG appli-
cation at the primary health care (PHC) level prior to
transport compared to later NASG application at the re-
ferral hospital (RH) level [5]. This study was conducted
in Zambia and Zimbabwe, where the maternal mortality
ratio is 591 and 960 per 100,000 live births respectively
[14,15]. We used an econometric approach to evaluate
the incremental cost-effectiveness of application of the
NASG at the primary health care center (PHC) com-
pared to waiting until the patient arrives at the RH. We
hypothesized that early application of the NASG at the
PHC would be more cost-effective than later application
of the NASG at the RH.patient.
Table 1 Per-protocol study characteristics
Early application Later application
n (%) n (%)
N° of women 366 466
Zambia 200 327
Zimbabwe 166 139
Mean age (standard deviation) 26.9 (5.9) 27.2 (6.3)
Median parity (IQR) 2 (1–3) 2 (1–3)
Gestational age (≥24 weeks) 37.7 (2.6) 37.4 (2.9)
Diagnosis
Complications of abortion*** 15.6% 36.2%
Postpartum uterine atony*** 42.1% 28.7%
Retained placenta* 25.1% 19%
Lacerations/Genital trauma** 13.1% 7.5%
Placental abruption 0.8% 4.5%
Placenta previa 0.8% 1.1%
Ectopic pregnancy 0.5% 1.3%
Ruptured uterus 0.3% 1.2%
Placenta accreta* 1.4% 0.0%
Molar pregnancy 0.3% 0.4%
Median (IQR) estimated revealed
blood loss at study entry (ml)
500 (480–700) 500 (500–800)
***p < 0.001, **p < 0.01, *p < 0.05.
Note: Wilcoxon Rank Sum test utilized to test all continuous variables due to
non-normality. Chi-square test used for categorical values except where noted.
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Design of clinical study
The clinical data for this study was approved by the
institutional review boards (IRBs) affiliated with the
following institutions: University of California, San
Francisco; University of Zambia, Lusaka; University of
Zimbabwe-UCSF Collaborative Programme on Health
Research; and the Department of Reproductive Health
and Research of the World Health Organization. The cost
data collected for this study did not involve human sub-
jects, and was thus exempt from IRB oversight.
This cost-effectiveness analysis builds on a previously
reported clinical trial, summarized here. The clinical trial
data belongs to UCSF and is freely available with a UCSF
data sharing agreement. The cluster-randomized con-
trolled trial of 38 PHCs in Zimbabwe and Zambia en-
rolled patients from 2009 to 2012. Eligible PHCs were
peri-urban with at least 500 annual deliveries that re-
ferred obstetric hemorrhage (OH) cases (≥500 mL blood
loss) to one of five study regional hospitals. Participants
were admitted at the PHC and were consenting women
with any obstetric hemorrhage etiology and hypovolemic
shock. Women with antepartum hemorrhage with a viable
fetus were excluded. PHCs were randomized to either
the early application or later application group using a
covariate-constrained procedure to ensure balance across
intervention arms on number of deliveries, number of de-
liveries per midwife, distance to referral hospital (RH), and
proportion of OH cases expected [16].
Women who presented at the PHC at < 24 weeks ges-
tation (ectopic pregnancy, complications of abortion, or
trophoblastic/molar pregnancy) were enrolled in the
outpatient department, while women at ≥ 24 weeks were
enrolled in the maternity department. Midwives at the
PHC were trained to treat PPH with uterotonics and IV
fluids, repair first- and second-degree perineal lacera-
tions, and refer any patient with estimated blood loss >
500 mL to the RH. PHCs were not equipped to provide
blood transfusions, surgery, or manual vacuum aspiration
(MVA). Each PHC had access to a shared ambulance sys-
tem to transfer patients to the RH.
All eligible women had a perineal pad applied at study
entry in the PHC to measure blood loss. Women in the early
application arm received the NASG (Zoex Corporation,
Coloma, CA 95613, USA) at the PHC and women in the
later application arm received it at the RH per treatment
protocol. All women were referred to the RH and were
transported by ambulance, private vehicle, or taxi. Oxy-
gen, IV fluids, uterotonics or uterine massage for uterine
atony, suturing of lacerations, manual removal of placenta
or retained tissues, MVA, surgery, and blood transfusions
were available as needed at the RH. More detailed infor-
mation regarding the design of the CRCT is provided else-
where [5].We use a per-protocol analysis [17]. Characteristics of
women were similar between early and later NASG ap-
plication groups (see Table 1) except for hemorrhage eti-
ology. The early application group was composed of a
higher proportion of women with uterine atony (42.1%
vs. 28.7%) and a lower proportion with complications of
abortion (15.6% vs. 36.2%) compared to the later applica-
tion group.
Effectiveness
Disability-adjusted life years (DALYs) without age-weighting
were used to quantify the burden of disease as a dis-
counted sum of the number of years of life lost (YL) from
early death and years lost due to disability (YLD) [18]. The
timeframe of this analysis was the four-year period of the
intervention. Disabilities over the women’s life were con-
sidered. YL was calculated as the difference between the
woman’s age and her age-adjusted life expectancy within
her country of residence for those women who died dur-
ing the study. YLD was constructed as a composite of the
morbidities for each woman who survived. This includes
acute renal failure, acute respiratory distress syndrome,
heart failure, cerebral impairment (seizures, unconscious-
ness, motor/cognitive loss), and severe anemia. The rate
of severe anemia was defined as hemoglobin value less
than 7.0 g/dL at hospital discharge.
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ences between earlier and later NASG application across
mortality and morbidity outcomes. The odds of death in
the early application group were 64% lower (OR 0.36
(95% CI: 0.08 – 1.53) than the later application group
(Table 2). There were no morbidities in the early appli-
cation group and 0.2% in the later application group.
There was no statistically significant difference in severe
anemia at discharge between groups. As morbidities and
mortalities were rare, there may have not been adequate
statistical power to detect an effect [5]. There was no
statistically significant difference between minutes from
study entry to death or study exit between the two groups;
however, women in the early application group recovered
from shock at a significantly faster rate, 165 min for early
application vs. 209 min for later application (OR 1.28
(95% CI: 1.05-1.57). On average, the later application
group received the NASG 2.5 hours after the early appli-
cation group.
Cost
We estimated costs using micro-costing methods. Re-
source use was estimated from clinical trial records. Unit
costs were collected from pharmacies, blood banks, and
hospital administrators in local currencies and converted
into international dollars [19]. Costs of clinical resources
at the PHC and RH were summed for each individual
(Table 3). As the NASG was applied to both groups,
only the timing differed; costs of the NASG (material/
cleaning/training) were estimated and described below
for reference only.
Cost of the NASG
The material cost of the NASG per use was estimated
as $1.04, based on an approximate price of $75 and






Anemic at discharge 74/321 (23.1%)
Emergency hysterectomy 1/210 (0.4%)
Time variables (mean minutes)
Study entry to death 282
Study entry to shock recoveryα 165 (90–279)
Study entry to exit 608.1
Study entry until NASG 2.4
αMedian (IQR); βHazard Ratio.communication Neil McConnochie, BlueFuzion to Suellen
Miller). The cost of cleaning the NASG included bleach,
bucket for immersion, personal protection equipment, and
personnel, and was estimated at $0.50 per use. The total
estimate for cost of NASG was $1.54 per use.
Training costs included transportation, facilities, mate-
rials, and personnel costs. The model assumes training
has a 10-year life, which is conservative given that train-
ing is not designed to require a refresher. Estimates of
training cost per patient were based on actual costs col-
lected from one facility where two hundred participants
attended a stand-alone (NASG only) training. The base-
case estimate for the cost of training per NASG use was
$1.62.
Clinical resource costs
Costs of uterotonics, oxytocin per ampoule (10 IU) and
misoprostol per dose, were collected from hospital phar-
macies and hospital administrators in one facility in
Zambia and one facility in Zimbabwe. Cost of blood
transfusions was based on cost per unit of blood in each
country during the study period. The cost of one unit of
blood and uterotonics in Zimbabwe were significantly
higher than in Zambia. In Zimbabwe blood cost $135
for the first unit and $90 per each additional unit, com-
pared to $42 per unit in Zambia. Blood was not always
available during the study period.
Emergency hysterectomy (EH) costs for complications
due to intractable uterine atony and complications of
abortion were collected. Costs include personnel, equip-
ment, anesthesia, and operating room costs. Emergency
hysterectomies were conservatively estimated to require
6 personnel over 60 to 90 minutes. No other surgeries
were included in this analysis, as etiologies differed, and
some etiologies require surgery (ruptured uterus, rup-
tured ectopic pregnancy).Later application Odds ratio (95% CI) p-value




68/322 (26.8%) 1.10 (0.61 – 1.99) 0.74
0/295 (0.0%)
391
209 (114–386) 1.28 (1.05-1.57)β 0.015
608.8
144.1
Table 3 Unit costs by country, 2010 (IU)1
Costs Zambia Zimbabwe
1. NASG per use2 $1.54 $1.54
2. Training per use3 $1.62 $1.62
3. 10iu Oxytocin $0.20 $3.00
4. 0.2 mg Ergometrine $0.20 $3.75
5. Misoprostol $0.19 $0.81
6. 1 unit of blood (450 ml) $42 $112.504
7. Emergency hysterectomy $36.56 $28.44
1International dollars.
2Cost is amortized over 72 uses and includes cleaning.
3Averaged across countries and includes provider opportunity cost.
4Mean of first 2 units shown; actual costs in analysis are $135 for first unit and
$90 per each additional unit.
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We estimated a series of models using Stata 13.0 (StataCorp,
College Station, TX, USA). We anticipated that variances
would differ across clusters due to variations in adherence
to treatment protocol; we include random effects to allow
individual-level differences to vary across clusters [20].
The general models for the random effects specifications
are as follows:
Eic ¼ β0 þ β1J c þ β2Zimc þ εc
þ μic Effectiveness : Models 1 − 4a½ 
Cic ¼ δ0 þ δ1J c þ δ2Zimc þ εc
þ μic Cost : Models 5 − 8a½ 
where Eic is the probability of a disability-adjusted life
year of individual i in cluster c and Cic is the costs of in-
dividual i in cluster c; Jc is an intervention indicator for
cluster c where j = 1 for early application group and j = 0
for later application group; Zimc is an indicator for
Zimbabwe (1 = Zimbabwe, 0 = Zambia) for each cluster
c; and uic is the error term.
In order to determine Eic, the probability of a disability-
adjusted life year of individual i in cluster c, we specified 4
random intercept models. In Model 1, the model was spe-
cified as above but excluded the country indicator. In
Model 2, we added the country indicator. In Model 3, we
estimated an interaction term between country indicator
Zimc and early application indicator Jc to understand
country-specific effects of early application. In Model 4,
we omitted the country indicator and instead used 4 refer-
ral hospital indicators, RHc, where the Lusaka hospital was
the reference. We re-specified Model 4 for Zambia only
(Model 4a) to improve statistical power as 13 of the 15
deaths occurred in Zambia. Models 5-8a were specified
identical to Models 1-4a substituting cost of individual i in
cluster c for outcome. We used a likelihood ratio test to
compare model fit for Models 1–4 and 5–8.We compared the effectiveness and costs between the
earlier and later NASG application groups to calculate
the incremental cost-effectiveness ratio (ICER) [21]. The
ICER is the difference between the costs and effective-
ness of the groups, given by δ1/β1.
We conducted a sensitivity analysis by simulating
probabilistic clinical resource costs and mortalities to
provide insight to their contribution to the ICER. We
varied the unit cost of blood from $20 to $200 while
keeping the blood transfusion rate (number of units per
individual) and all other variables constant to reflect the
probable range of costs of blood within sub-Saharan
Africa. We also assessed how varying the relative odds
ratio of death given timing of NASG application would
impact the ICER, and whether the results from our
primary models were consistent when stratifying by
severe shock at study entry, defined by mean arterial
pressure <60 mm Hg.
Results
Effectiveness
The model that fit the data best (Model 4) showed that
women in the early application group had 0.712 fewer
DALYs than those in the later application group (p <
0.05; Table 4). In the unadjusted model, the early appli-
cation group experienced 0.38 DALYs and the later ap-
plication group experienced 0.97 DALYs due to obstetric
hemorrhage (not shown). Thus, early application averted
0.59 DALYs (95% CI: −1.58 to 0.39), although this differ-
ence was not statistically significant (Table 4). The rela-
tively few deaths (n = 15) and morbidities (n = 1) in this
trial precluded precise estimation of DALYs, demonstrated
by the wide confidence intervals around each of the point
estimates. Adding the country indicator for Zimbabwe to
control for between-country variation (Model 2) and
modeling an interaction effect between country and early
application (Model 3) did not improve the fit of the model
and the coefficient for the early application remained
insignificantly different from zero. The best-fit model
was Model 4, which accounted for referral hospital ef-
fects using the Lusaka hospital as reference. Women
in the early application group averted 0.712 DALYs
(p < 0.05) compared to those in the later application
group. In Zambia only (Model 4a), we found a mar-
ginally significant effect (p < 0.10) of early application
of 0.729 DALYs averted.
Costs
Mean costs, by type
The mean treatment cost per woman across both groups
was $51.17. The median cost was lower, at $19.61 (IQR
$8.02 – $91.62), indicating that a small number of
women had very high costs. The median cost was $19.62
(IQR $13.62- $25.62) in Zimbabwe and $8.82 ($8.02-
Table 4 Random effects models for Disability-Adjusted Life Years (DALYs)
(1) (2) (3) (4) (4a)3
Early application −0.591 (0.51) −0.553 (0.50) −0.688 (0.624) −0.712 (0.326)** −0.729 (0.461)*
Zimbabwe1 −0.504 (0.55) −0.670 (0.760)
Zimbawe#EarlyApplication 0.425 (1.091)
Lusaka2 ref ref
Harare 1 0.112 (0.536)
Harare 2 −0.595 (0.383)
Copperbelt1 −0.204 (0.525) 0.203 (0.634)
Copperbelt2 −0.171 (0.511) −0.166 (0.608)
Constant 0.967 (0.344)** 1.13 (0.390)** 1.188 (0.421)** 0.955 (0.262)*** 0.961 (0.324)***
Country control no yes yes no no
RH controls no no no yes yes
***p < 0.01, **p < 0.05, *p < 0.1.
Note: Standard errors are in parentheses.
1Reference group is Zambia.
2RH include Lusaka (n = 341), Harare1 (n = 93), Harare2 (n = 211), Copperbelt1 (n = 82), Copperbelt2 (n = 95).
3Model 4a is the same as model 4, but restricted to Zambia only.
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was similar across both countries at $54.56 for the early
application group and $52.61 for the later application
group (Table 5). Stratified by country, the treatment
costs in Zimbabwe were $17.16 lower for early vs. later
application (p = 0.275) and $15.51 higher for early vs.
later application groups in Zambia (p = 0.001).
In Zimbabwe, the cost of a unit of blood was high and
very few (7%) individuals received transfusions. In Zambia,
roughly half of the women received blood transfusions
and a slightly higher (statistically insignificant) proportion
of women in the early application group received blood
transfusion. Across both countries and intervention arms,
three out of four women received an uterotonic; more
than 97% of those receiving an uterotonic received oxy-
tocin. In Zambia, costs of uterotonics are marginal.
In Zimbabwe, costs per uterotonic dose were 4–15 times
higher, although rates and costs did not differ meaning-
fully across intervention groups.
Cluster-specific random-effects models
Early application of the NASG cost $15.51 more than
later application based on estimates from the best-fit
model (Model 7). In our first cost model, treatment
costs for the early application group were $1.96 higher
on average than for the later application group, but this
difference was not statistically significant (Table 6;
Model 5). The difference in treatment costs across the
intervention groups remained insignificant when con-
trolling for country-specific costs (Model 6). Adding an
interaction term between the country indicator and tim-
ing of application in Model 7 improved the fit of the
model. We found a significant interaction effect betweencountry and timing of application (Model 7), indicating
the average treatment cost for the early application
group in Zimbabwe was $32.67 less than the later appli-
cation group (p < 0.01), while in Zambia, the mean treat-
ment cost of the early application group was $15.51
higher (marginally significant, p < 0.1) than the later ap-
plication group.
The above estimates may be biased if the availability
and use of resources varied significantly across referral
hospital. In Model 8, we substituted the country indica-
tor with 4 referral hospital indicators (RHc) using the
Lusaka hospital as reference and this improved the fit of
the model compared to the simple model (Model 5).
Compared to the Lusaka hospital, the Harare1, Copperbelt1,
and Copperbelt2 hospitals had significantly lower treat-
ment costs ($38.75, $36.31, and $19.93, respectively);
however, there was no significant difference in cost by
timing of application within this model. In Model 8a
(restricted to Zambia), the mean treatment cost for
the early application group was significantly higher
than the later application group, at $76.49 vs. $60.45
respectively. Consistent with Model 8, Model 8a shows
significantly lower treatment costs for the Copperbelt1
and Copperbelt2 hospitals compared to the Lusaka
hospital.
Incremental Cost-Effectiveness Ratio (ICER)
Across both countries, early NASG application costs
$21.78 per DALY averted ($15.51/0.712) compared to
late application based on the results from our best-fit
models. In Zambia, early NASG application costs $22.00
for each DALY averted compared to late application
($16.04/0.729 DALYs). We do not have enough
Table 5 Costs and clinical resources, by NASG timing group and country
Costs and clinical resources All women Zimbabwe Zambia
832 women in 38 clusters 305 women in 12 clusters 527 women in 12 clusters
Late Early p-value Late Early p-value Late Early p-value
1. Number of women 466 366 139 166 327 200
2. Proportion of women who received
any blood transfusions
36.1% 27.9% 7.9% 5.8% 48.0% 61.0%
3. Mean cost of blood transfusions
(of those who received blood)
$114.88 $115.49 0.967 $500.91 $441.25 0.667 $87.83 $94.14 0.240
4. Proportion of women who received
any uterotonics
78.8% 78.4% 82.0% 82.5% 77.4% 75.0%
5. Mean cost of uterotonics
(of those who received uterotonics)
$4.53 $7.42 <0.001 $13.46 $14.85 0.332 $0.52 $0.64 < 0.001
6. Mean cost per woman $52.61 $54.56 0.765 $58.30 $41.14 0.275 $50.19 $65.70 < 0.001
(43.6 - 61.6) (45.6 - 63.5) (31.3 - 85.2) (23.9 - 58.3) (44.2 - 56.2 (57.8 - 73.5)
Note: Wilcoxon Rank Sum test utilized to test all continuous variables due to non-normality.
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for Zimbabwe.
Sensitivity analyses
First, to assess for potential non-adherence to treatment
protocol that might affect a per-protocol analysis, we
ran the same models using an intent-to-treat (ITT) ana-
lysis. There were no significant differences in effects be-
tween the approaches; the estimates of the per-protocol
analysis were attenuated slightly by the smaller sample
size, as expected. The low attrition rate and negligible
degree of bias suggest that our per-protocol results are
what we would expect in a clinical practice setting.
We reran Models 1–8, stratified by shock status.
Women who entered the study with mean arterial blood
pressure of less than 60 are considered to be in severeTable 6 Random effects models for cost
Model 5 Model 6








Constant 52.61 (4.16)*** 54.88 (4.80)***
Country control no yes
RH controls no no
***p < 0.01, **p < 0.05, *p < 0.1.
Note: Standard errors are in parentheses.
1Reference group is Zambia.
2RH include Lusaka (n = 341), Harare1 (n = 93), Harare2 (n = 211), Copperbelt1 (n = 8
3Model for Zambia only.shock. There were no differences in estimates in our cost
models. However, the DALYs averted rose from 0.712 to
0.844 in the best-fitting effectiveness model. This sug-
gests that, in this sample, early application of the NASG
before transport appeared to have greater benefit for
women who did not enter in severe shock.
The ICER of applying the NASG early compared to
later was sensitive to the unit cost of blood transfusions
and ranged from $9.22-87.85 (see Figure 2). In this case,
it appeared less cost-effective when the cost of blood in-
creased because there was a slightly higher blood trans-
fusion rate in the early application group. The baseline
odds ratio of death with the late application of NASG is
2.77 times higher than early application. We imputed
deaths in the timing groups to create synthetic odds ra-
tios ranging from 1.68 to 3.74, which were selectedModel 7 Model 8 Model 8a3






−36.31 (11.40)*** −35.84 (6.62)***
−19.93 (10.91)* −21.92 (6.35)***
50.19 (5.17)*** 63.34 (5.62)*** 60.45 (3.38)***
yes no no
no yes yes
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Figure 2 Sensitivity analysis of cost of 1 unit of blood. The cost per unit of blood causes the ICER to increase because there was a slightly
higher blood transfusion rate in the early application group. The base-case value is indicated in purple.
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odds of death in the early application group decreases
relative to the group with later application (Figure 3). In
other words, as early application becomes more effect-
ive, it becomes more cost-effective.
Discussion
Within a cluster randomized trial, early application of
the NASG at the primary care level versus waiting until
referral hospital arrival had a cost-effectiveness ratio of
$21.78 per DALY averted ($15.51 in added costs divided
by 0.712 DALYs averted per woman, both statistically
significant). In Zambia, early NASG application cost a
nearly identical $22.00 for each DALY averted compared
to late application ($16.04/0.729 DALYs). This ratio is
considered “very cost-effective” by the WHO definition
of annual GDP per capita [22]. In Zimbabwe, point esti-
mate results suggested similar benefits, but were not sta-
tistically significant, which may be due to low statistical
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Figure 3 Sensitivity analysis of effectiveness. The cost per DALY averted
relative to the odds of death in the early application group. The base-caseMean treatment costs were patterned differently by
country, where the early application group was associ-
ated with somewhat lower but not statistically different
costs in Zimbabwe ($17.16), but significantly higher
costs ($15.51) in Zambia in our descriptive analyses, and
consistent with the random-effects Model 7.
The difference in costs across the two countries is
largely driven by the rate and cost of blood transfusion
(Figure 2). This is not surprising given that blood trans-
fusion is the definitive treatment for hypovolemia. In
Zimbabwe, very few women received blood (5.8% and
7.9%, respectively in the early and late application
groups) compared to Zambia (61.0% and 48.0%, respect-
ively). Some of this difference may be explained by the
higher per unit cost of blood in Zimbabwe compared to
Zambia ($113 vs. $42). We are not able to directly quan-
tify the extent to which blood availability contributed to
this difference in rates. However, our analysis that took
into account referral hospital (RH) effects revealed
higher costs in the Lusaka RH versus the Copperbelt2.5 3 3.5 4 
 late application compared to early application 
falls as the odds of death in the late application group increases
value is indicated in purple.
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national blood bank and has better access to blood, we
suspect this is likely due to higher proportions of women
at the Lusaka RH receiving blood transfusions. Local
blood availability and costs should be contextualized to
the country and region as lack of blood is common in
low- and middle-income contexts and is a major driver
of hemorrhage-related mortality and morbidity [23].
We found that mild shock (MAP > = 60) on presenta-
tion was associated with more DALYs averted per women
who received the NASG earlier. This may be due to the
considerable benefit of early application of the NASG to
prevent worse shock during transport to definitive treat-
ment. Importantly, this finding is inconsistent with previ-
ous results from multiple studies, which found greater
NASG benefits for women in severe shock when applied
at the RH level only [24]. Therefore, we found NASG hav-
ing important value for women in severe and mild shock.
Results from the previous cost-effectiveness analysis
on data from the referral hospital level, which compared
NASG application to no application, determined the
intervention to be cost saving (Egypt) or extremely cost-
effective (Nigeria at $3.13 per DALY averted) [13]. As
expected, our current analysis of data from Zambia and
Zimbabwe of early NASG application at the PHCs com-
pared to later NASG application at the RH indicates that
the additional costs associated with expanding the
NASG to the PHC level is well within the WHO stan-
dards for very cost-effective [25]. Our country-level find-
ings suggest that NASG intervention at the PHC may
even be cost saving in Zimbabwe; however, the low rate
of mortalities and morbidities in that subsample renders
the findings imprecise. Although the results of the
cluster-randomized trial lacked statistical significance,
the large observed reduction in mortality (64%) was con-
sistent with statistically significant outcomes from earlier
studies conducted at the RH level [6,7]. Furthermore,
earlier NASG intervention in the CRCT was significantly
associated with faster recovery from shock, which sup-
ports the plausibility of a meaningful reduction in mor-
tality (Table 2).
Policy makers with limited resources may need to
make decisions about which levels of the health care
system to place the NASG. Should NASG be only at
the RH? At both the RH and the PHC? Or should it be
used at even lower levels of the health care continuum?
Should NASGs be on ambulances or other transport?
Given the strength of the evidence for cost-effectiveness
at the referral hospital level, the decision to implement the
NASG within the RH level is straightforward. In deciding
whether to incur the additional costs of adding the NASG
at the PHC level, policy makers may want to consider sev-
eral factors: 1) the proportion of women who first seek
care at the PHC level; 2) the proportion of maternaldeaths from hemorrhage which occur at the PHC, during
transit, or within the first 2 hours after admission to the
RH; 3) the clinical capacity for resuscitation at the PHC
level; 4) average transport times from the PHC to the RH;
and 5) the length of delays in admission and receipt of
quality definitive care including blood transfusions and
surgery once at the RH. Greater benefits will be obtained
from situating the NASG at the PHC level in contexts
where the first contact with care is at the PHC level, or
where receipt of definitive care is delayed by transporta-
tion, less optimal resuscitation or other time delays faced
at the PHC or RH. Data on situating the NASG within
emergency transport are not available.
There are several limitations to this study. The major
limitation was low power due to a smaller than expected
number of deaths in the CRCT. Also, the study was
not designed to explicitly study the availability and
provision of blood transfusion; thus, we had less reliable
information about the availability of blood transfusions.
Given that the earlier and later application arms occurred
simultaneously and blood transfusions do not appear to be
clustered within any set of patients referred from a PHC,
we expect non-differential bias across intervention arms.
The analysis did not include the economic benefits
and costs from the patient’s perspective. It is likely that
early application of the NASG would have health and
economic benefits for women and their families.
The costs for using the NASG will fluctuate, but may
continue to decrease, as competitive sales pricing has re-
sulted in prices as low as $57.50. (Personal communica-
tion Neil McConnochie, Blue Fuzion to Suellen Miller.)
Incorporating training into ongoing Emergency Obstetric
Newborn Care, Life Saving Skills, and pre-service training
will eventually eliminate a separate price for stand-alone
in-service NASG training. The differential costs for blood,
medications, and surgery will be highly context specific.
Conclusion
Applying the NASG earlier at the Primary Health Care
level for women in hypovolemic shock secondary to ob-
stetric hemorrhage instead of waiting until the woman
has been transferred to the Referral Hospital has the po-
tential to be a cost-effective decision across many clinical
settings. Our evidence from Zambia strongly supports this
conclusion. Evidence from Zimbabwe is suggestive but
not statistically significant. As the NASG is designed to re-
verse shock and decrease further bleeding for women in
obstetric hemorrhage, patients who have received the
NASG earlier may be better able to survive delays in
reaching definitive care at the RH and recover more
quickly from shock, all at a cost that is highly acceptable.
Policymakers and administrators need to consider a var-
iety of factors to determine which levels of their health
system will cost-effectively save the most lives.
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